Bayer Created Ruveon — What That Means for Your Roundup Cancer Lawsuit
You used Roundup. Maybe for years — on the farm, at the landscaping company, in your own backyard. Then the diagnosis came: non-Hodgkin lymphoma. A blood cancer you never saw coming. And now you are reading that Bayer, the company that inherited the Roundup business when it bought Monsanto, is spinning its U.S. glyphosate operations into a new entity called Ruveon. The first question that hits you is the sharpest one: is this the company trying to make itself harder to sue?
We are going to answer that question directly, because you deserve a straight answer — not a hedge. The short version: corporate restructuring does not erase liability. Bayer remains the parent entity. Monsanto designed, tested, marketed, and labeled Roundup for decades. The tens of thousands of lawsuits already filed — and the ones still being filed — name Bayer as the successor that assumed Monsanto’s liabilities when it acquired the company in 2018. A new subsidiary called Ruveon does not change who is on the hook for what happened before the ink dried on that restructuring. But it does add a layer of corporate complexity that your lawyer needs to understand and navigate — because the company certainly built it with its own defense in mind.
If you or someone you love was diagnosed with non-Hodgkin lymphoma after years of Roundup exposure, call us at 1-888-ATTY-911. The consultation is free. We do not get paid unless we win your case. And we work in English or Spanish — because this question matters in every language.
What the Bayer-Ruveon Restructuring Actually Is
Bayer Group has announced that it is consolidating its U.S. glyphosate business into a distinct entity operating under the name Ruveon. In plain terms, the company is reorganizing how it holds and operates the Roundup and glyphosate product line in the United States. This is a corporate-structure decision — a business move about how assets, operations, and liabilities are allocated within the Bayer corporate family.
What it is not, on its face, is a bankruptcy — unlike the Johnson & Johnson talc litigation, where the company created a separate entity called LTL Management LLC to warehouse liability and file for Chapter 11. Bayer has not taken that route with Ruveon, at least not as of what is publicly known. But the restructuring still demands scrutiny, because the timing and structure of any corporate reorganization can become a litigation issue in itself.
Here is what we look at when a defendant restructures while facing tens of thousands of pending lawsuits:
The asset-transfer structure. When a parent company moves a product line into a new subsidiary, the internal agreements that govern that transfer — what assets go in, what liabilities stay behind, who indemnifies whom — are the documents that tell us whether the restructuring is a legitimate business reorganization or a liability-shielding maneuver. These agreements may be sealed or confidential, but they are discoverable in litigation. A preservation letter demanding these documents goes out early.
Whether pending claims are assumed or carved out. Does Ruveon assume responsibility for existing Roundup litigation? Does Bayer retain it? Or is the liability left in a legacy entity with diminishing assets? The answer to that question shapes the entire strategy for pending and future plaintiffs.
Whether the restructuring creates a fraudulent-transfer or successor-liability claim. If Bayer transfers the profitable glyphosate business to Ruveon while leaving the tort liability in an entity with insufficient assets to satisfy judgments, plaintiff counsel may pursue fraudulent-transfer theories. The core legal principle is simple: you cannot strip assets out of an entity that owes people money and leave the debts behind with nothing to pay them.
The timing. A restructuring that happens while a defendant is facing 4,000+ pending federal lawsuits, an active Supreme Court preemption case, and ongoing settlement negotiations is not a routine business decision. The timing is itself evidence of intent — and a court looking at that timing will ask whether the structure was designed to affect the litigation landscape.
The corporate-structure analyst in us looks at Ruveon and sees a move that could mean any of three things: a genuine operational consolidation, a strategic firewall designed to insulate the glyphosate business from future liability, or a step in a sequence that may eventually lead to a more aggressive liability-containment strategy. We do not know which yet. What we know is that the documents that answer the question exist right now, and they need to be preserved.
Background: How Bayer Inherited the Roundup Problem
To understand what Ruveon means, you need to understand how Bayer got here. Monsanto Company developed and marketed Roundup for decades. Roundup’s active ingredient is glyphosate — a broad-spectrum herbicide that became the most widely used weedkiller in the world. Monsanto engineered “Roundup Ready” crops to survive glyphosate spraying, which drove usage to extraordinary volumes across American agriculture.
In 2015, the International Agency for Research on Cancer (IARC) — the cancer-research arm of the World Health Organization — classified glyphosate as “probably carcinogenic to humans,” placing it in Group 2A. That classification did not come out of nowhere. It was based on a review of the available scientific evidence, including studies showing a statistical association between glyphosate exposure and non-Hodgkin lymphoma in exposed workers.
In 2015, IARC classified glyphosate as “probably carcinogenic to humans” (Group 2A), finding limited evidence of cancer in humans and sufficient evidence in experimental animals.
The EPA has historically taken a different position, classifying glyphosate as “not likely to be carcinogenic to humans.” That tension — between the world’s leading cancer research body and the U.S. pesticide regulator — is the scientific fault line the entire Roundup litigation runs along. Plaintiffs argue that the IARC classification, combined with Monsanto’s own internal research and the epidemiological literature, established enough evidence of cancer risk that the company had a duty to warn users. Monsanto and Bayer argue that the EPA’s position controls and that the science does not support a causal link.
Bayer acquired Monsanto in 2018 for approximately $63 billion. With that acquisition, Bayer assumed Monsanto’s liabilities — including the Roundup product-liability claims that were already beginning to surface. Bayer did not buy a clean company. It bought a company with a product line that would generate tens of thousands of lawsuits, billions in settlements, and a Supreme Court case on federal preemption that remains undecided.
As of June 2026, the federal multidistrict litigation — MDL-2741, In re: Roundup Products Liability Litigation, consolidated in the Northern District of California before Judge Vince Chhabria — showed approximately 3,909 actions pending. Tens of thousands more cases have been filed in state courts or resolved through settlement programs. Bayer has paid billions in settlements, but the litigation is far from over. And the restructuring into Ruveon is happening against that exact backdrop.
Successor Liability: Can Bayer Hide Behind Ruveon?
This is the question every Roundup plaintiff asks when they hear about Ruveon, and the answer requires us to look at the doctrine of successor liability — the legal principle that prevents a company from shedding its obligations by shuffling assets and entities.
When Bayer acquired Monsanto in 2018, it did not just buy Monsanto’s products and patents. It bought Monsanto’s legal exposure. The general rule of corporate acquisitions is that when one company acquires another, the acquiring company assumes the acquired company’s liabilities — unless the acquisition agreement specifically allocates liabilities differently, and even then, the allocation is typically between the two companies, not binding on third-party tort claimants who were never party to that agreement.
The key legal principles that protect Roundup plaintiffs against corporate restructuring:
Bayer is the parent. Regardless of what subsidiary structure Bayer creates — whether it is Monsanto, Ruveon, or some future entity — Bayer Group is the ultimate parent corporation. It has the balance sheet. It made the decision to acquire Monsanto. It assumed the liability. A subsidiary does not shield the parent from claims arising from the parent’s own conduct or from liabilities the parent assumed.
The duty to warn runs to the manufacturer. Roundup was designed, tested, manufactured, marketed, and labeled by Monsanto. Bayer acquired that company and its obligations. The failure-to-warn theory — that Monsanto knew or should have known about the cancer risk and failed to adequately warn users — attaches to the entity that made and sold the product. Ruveon does not erase what Monsanto did or what Bayer assumed.
Fraudulent transfer law protects plaintiffs. If a company transfers assets out of an entity that owes tort judgments, leaving that entity unable to pay, the transfer can be challenged as a fraudulent conveyance. Every state has a fraudulent-transfer statute — some based on the Uniform Fraudulent Transfer Act, others on its successor, the Uniform Voidable Transactions Act. The core principle is the same: you cannot move the money out of the entity that owes the debts.
The corporate veil can be pierced. In extreme cases — where a parent corporation uses a subsidiary as a mere shell, undercapitalizes it, or uses it to perpetrate a fraud — courts will pierce the corporate veil and hold the parent directly liable. This is a high bar, but it is a tool that exists when restructuring crosses from legitimate business strategy into abuse of the corporate form.
The restructuring itself can become evidence. If Ruveon is structured in a way that suggests Bayer is trying to limit its exposure to future glyphosate claims, the timing, structure, and internal communications surrounding the restructuring become evidence — evidence of consciousness of liability, evidence of intent to shield assets, and evidence that supports punitive damages theories. Juries understand what it looks like when a company reorganizes its liabilities while telling the public its product is safe.
The bottom line: we do not concede corporate structure. If Bayer created Ruveon to insulate itself, we investigate the structure, demand the documents, and pursue every theory — successor liability, fraudulent transfer, veil piercing, and direct corporate negligence — that holds the right entities accountable. The name on the entity may change. The obligation to the people who were injured does not.
The Supreme Court Preemption Fight: Monsanto v. Durnell
There is a case pending before the United States Supreme Court right now that could reshape every Roundup lawsuit in the country — and you need to know about it, because it may affect the timeline and strategy of your case.
The case is Monsanto Company v. Durnell, No. 24-1068. The Supreme Court granted certiorari on January 16, 2026, and heard oral argument on April 27, 2026. A decision is expected by the end of the term. As of this writing, the case is undecided — we do not state an outcome because there is not one yet.
The question before the Court is whether FIFRA — the Federal Insecticide, Fungicide, and Rodenticide Act, the federal law that governs pesticide registration and labeling — expressly preempts state-law failure-to-warn claims when the EPA did not require a cancer warning on the product label.
Here is why this matters to you:
Bayer’s strongest defense in Roundup litigation is the argument that federal law controls pesticide labeling. If the EPA approved Roundup’s label without a cancer warning, and if federal law says you cannot add state-law requirements that conflict with the federal label, then — Bayer argues — a state-law lawsuit claiming “you should have warned about cancer” is preempted. The company’s position is essentially: the federal government approved our label, and federal law says that label controls, so you cannot sue us in state court for not adding a warning the federal government did not require.
Plaintiffs counter that FIFRA’s preemption clause is narrower than Bayer claims. They argue that FIFRA does not bar state-law claims that are consistent with FIFRA’s objectives — and that a failure-to-warn claim based on the manufacturer’s own knowledge of cancer risk is not the same as imposing a different labeling requirement. They also point to the CBE regulation — the “Changes Being Effected” provision that allows a manufacturer to strengthen its warning label unilaterally when it learns of new safety information — as evidence that the manufacturer was not locked into the EPA-approved label and could have warned on its own.
If the Supreme Court rules for Monsanto, state-law failure-to-warn claims could be significantly restricted or eliminated in some jurisdictions. If the Court rules for the plaintiffs, the existing litigation pathway remains intact and Roundup cases continue on their current track. If the Court issues a narrow ruling, the effect may be jurisdiction-specific and case-specific.
What this means for you practically: if you are considering a Roundup claim, the time to act is now — not after the Supreme Court rules. If the ruling restricts claims, cases filed before the decision may be in a stronger procedural posture than cases filed after. If the ruling preserves claims, the existing path continues. Either way, waiting is a strategic risk. The evidence in your case — your exposure history, your medical records, your purchase receipts — is not getting stronger with time. And the statute of limitations in your state is running regardless of what the Supreme Court does.
Who Can Still File a Roundup Cancer Lawsuit
The eligibility picture for Roundup litigation is broader than many people realize. You do not have to be a commercial farmer or a professional landscaper to have a claim. The core question is whether you had meaningful exposure to Roundup or glyphosate products and later developed non-Hodgkin lymphoma.
Who we see in these cases:
Farmers and agricultural workers who sprayed Roundup on crops over many seasons — often the highest-exposure group, because of the volume, frequency, and duration of use. The exposure pathway is direct: mixing and loading the concentrate, operating spray equipment, walking through treated fields, and absorbing glyphosate through skin and inhalation.
Landscapers and groundskeepers who used Roundup professionally — at parks, golf courses, schools, commercial properties, and residential developments. These workers often used Roundup daily or weekly for years.
Homeowners and gardeners who used Roundup regularly on their own property. A homeowner who sprayed Roundup every weekend for a decade is in a different exposure category than someone who used it once, but the question is whether the exposure was sufficient and sustained enough to plausibly contribute to the disease.
Nursery and greenhouse workers exposed to glyphosate in enclosed environments where concentration and inhalation exposure can be higher than outdoor use.
Maintenance workers, railroad workers, and utility workers who sprayed glyphosate along rights-of-way, tracks, and fence lines as part of their job duties.
The injury that drives these cases:
Non-Hodgkin lymphoma is the signature injury in Roundup litigation. NHL is a cancer of the lymphatic system — a group of blood cancers that includes diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and other subtypes. The scientific literature that IARC relied on when it classified glyphosate as Group 2A showed a statistical association between glyphosate exposure and NHL in exposed workers.
If you were diagnosed with NHL and have a history of significant Roundup use, the two facts that matter most are: (1) the duration and intensity of your exposure, and (2) the timing — when you were exposed relative to when you were diagnosed. Glyphosate exposure and NHL have a latency period, meaning the cancer may develop years after the exposure. That latency is why the discovery rule — which starts the statute-of-limitations clock when you discovered or should have discovered the connection between your illness and the exposure — is so important in these cases.
Families who have lost a loved one to NHL may have a wrongful-death claim, subject to the wrongful-death statute of limitations in their state — which is often shorter and more rigid than the personal-injury deadline. If your family member passed away from NHL and had a history of Roundup use, do not assume the deadline has passed. Call us. The discovery rule may apply, and the clock may have started later than you think. You can learn more about our wrongful death practice to understand how these claims work.
What Evidence to Preserve If You Used Roundup and Developed NHL
The evidence in a glyphosate case is different from a car-crash case. There is no skid mark to measure and no dashcam to pull. The proof is built from your own history — and the faster you document it, the stronger it is.
Product containers and packaging. If you still have Roundup bottles, jugs, or concentrate containers — keep them. The label on the container is evidence of what warnings were (or were not) present at the time you purchased the product. Photograph the labels. Do not discard the containers.
Purchase receipts and records. Any evidence of when and how much Roundup you bought is exposure proof. Credit card statements, hardware store receipts, agricultural supply invoices, employer purchase records — these establish the volume and timeline of your use. If you do not have receipts, think about where you bought it and whether the retailer might have records.
Employment and agricultural records. If you used Roundup as part of your job, your employment records may document your duties, your job title, and the duration of your employment in a position that involved herbicide application. Agricultural workers may have pesticide applicator licenses, spray logs, crop records, or employer documentation of chemical use. These records may exist in employer files, with state agricultural agencies, or with the EPA under pesticide-use reporting requirements.
Medical records. Your medical records establish the diagnosis, the date of diagnosis, the specific NHL subtype, your treatment history, and your prognosis. The pathology report from your biopsy is the definitive document — it identifies the exact cancer subtype, which matters for causation analysis. Your treatment records — chemotherapy, radiation, immunotherapy, stem-cell transplant — document the medical cost and the human toll.
Witness statements. Co-workers, family members, and neighbors who can describe your Roundup use — how often, how much, what equipment you used, whether you wore protective gear — are witnesses to your exposure. Their memories are best captured now, not years from now.
Corporate restructuring documents. In light of the Ruveon announcement, a new category of evidence matters: the internal Bayer documents that govern the restructuring. The entity-formation filings, the asset-transfer agreements, the liability-allocation provisions, and any internal communications about the purpose and timing of the restructuring. These are discoverable, but they are also the kind of documents that can be sealed, reorganized, or made difficult to access if a new entity’s document custodians are restructured along with the business. A preservation letter demanding these documents goes out early.
The Medicine: Non-Hodgkin Lymphoma and Glyphosate
Non-Hodgkin lymphoma is not one disease — it is a family of blood cancers that originate in the lymphatic system. The lymphatic system is the body’s immune network: lymph nodes, the spleen, bone marrow, and the thymus all produce and store the white blood cells that fight infection. NHL begins when a lymphocyte — a type of white blood cell — develops a genetic mutation that causes it to multiply abnormally and fail to die on schedule. The abnormal cells accumulate, form tumors in lymph nodes or other lymphatic tissue, and can spread to other organs.
The subtypes of NHL most relevant to glyphosate exposure include:
Diffuse large B-cell lymphoma (DLBCL) — the most common NHL subtype in adults, an aggressive cancer that requires immediate treatment. DLBCL presents as rapidly enlarging lymph nodes, often with systemic symptoms like fever, night sweats, and unexplained weight loss.
Follicular lymphoma — an indolent (slow-growing) subtype that may not require immediate treatment but is generally considered incurable. Patients live with the disease for years, requiring intermittent therapy.
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) — a cancer of B-cell lymphocytes that can present as either a leukemia (in the blood) or a lymphoma (in the lymph nodes).
Mantle cell lymphoma — a rarer, more aggressive subtype with a poorer prognosis.
The treatment reality:
NHL treatment depends on the subtype, the stage, and the patient’s overall health. For aggressive forms like DLBCL, first-line treatment typically involves R-CHOP chemotherapy — a combination regimen that includes rituximab (a monoclonal antibody), cyclophosphamide, doxorubicin, vincristine, and prednisone. This is six months of grueling treatment with significant side effects: nausea, hair loss, fatigue, immunosuppression, cardiac toxicity from doxorubicin, and nerve damage from vincristine.
For patients who relapse or do not respond to initial therapy, the treatment escalates to high-dose chemotherapy followed by an autologous stem-cell transplant — a process that involves harvesting the patient’s own stem cells, administering near-lethal doses of chemotherapy to wipe out the bone marrow, and then reinfusing the stem cells to rebuild the immune system. This is weeks in the hospital, months of recovery, and a permanent alteration of the patient’s health.
For some subtypes, CAR-T cell therapy — a revolutionary but harrowing treatment where the patient’s own T-cells are genetically engineered to attack the cancer — is an option. It is also a treatment that can cause cytokine release syndrome and neurotoxicity, and it costs hundreds of thousands of dollars.
The proof problem the defense exploits:
NHL is not rare. Approximately 80,000 Americans are diagnosed with NHL each year, and most cases have no identified cause. The defense in Roundup cases argues that any given NHL diagnosis is more likely than not idiopathic — meaning it arose from unknown causes, not from glyphosate. They point to genetic factors, other chemical exposures, viral infections, and immune-system disorders as alternative causes.
The plaintiff’s counter is the dose-response relationship. The scientific literature that IARC reviewed showed that workers with higher cumulative glyphosate exposure had higher rates of NHL. A plaintiff who can document years of heavy, direct exposure — mixing concentrate, spraying without protective equipment, working in treated fields — presents a stronger causation profile than a casual user. The toxicologist and the oncologist work together to build the specific causation opinion: that this person’s exposure was sufficient, that the timing is consistent with latency, and that the specific NHL subtype is the type the literature associates with glyphosate.
What the family sees:
NHL is a cancer that changes a person’s life permanently even when treatment succeeds. The fatigue can last for years after chemotherapy. The risk of relapse never fully goes away. The immune system may be permanently weakened. A person who went through R-CHOP and a stem-cell transplant may be alive but unable to return to the same work, the same activities, the same life. That is the human cost — and it is what the damages calculation is built to capture.
The Regulatory Framework: EPA vs. IARC
The regulatory landscape for glyphosate is defined by a fundamental disagreement between two authoritative bodies — and that disagreement is the scientific battleground of the entire Roundup litigation.
FIFRA and the EPA. Glyphosate is regulated by the U.S. Environmental Protection Agency under the Federal Insecticide, Fungicide, and Rodenticide Act. FIFRA governs the registration, labeling, and use of pesticides in the United States. Before a pesticide can be sold or distributed, it must be registered with the EPA, and the EPA must approve the product label — including any warning statements. The EPA has historically classified glyphosate as “not likely to be carcinogenic to humans.” That position has been the cornerstone of Monsanto’s and Bayer’s defense: the federal regulator reviewed the science and concluded glyphosate does not cause cancer.
IARC and the Group 2A classification. The International Agency for Research on Cancer — the specialized cancer agency of the World Health Organization — reviewed the scientific evidence on glyphosate in 2015 and classified it as “probably carcinogenic to humans” (Group 2A). IARC’s Group 2A category is reserved for substances where there is limited evidence of cancer in humans but sufficient evidence in experimental animals. Other substances in Group 2A include red meat, very hot beverages, and nighttime shift work. The classification is a hazard identification — it means the evidence supports a credible concern that the substance can cause cancer, not that every exposure will.
Why the tension matters in court. Plaintiffs argue that the IARC classification — combined with the epidemiological studies, the mechanistic evidence, and Monsanto’s own internal research — established enough evidence of cancer risk that the company had a duty to warn. They point out that IARC is the world’s leading cancer research body and that its methodology is specifically designed to evaluate cancer risk. They argue that the EPA’s position is not the final word on science and that FIFRA does not require a manufacturer to stay silent when it has evidence of cancer risk.
The defense argues that the EPA’s registration and labeling decision controls — that federal law preempts state-law claims that would impose a different warning requirement. This is the exact argument now before the Supreme Court in Monsanto v. Durnell.
The restructuring does not change the regulatory framework. FIFRA registration obligations attach to the product, regardless of the entity name. Whether the label says Monsanto, Bayer, or Ruveon, the same federal registration and labeling requirements apply. The regulatory status of glyphosate does not change because the corporate structure changed. What may change is who holds the registration, who is responsible for the label, and who is the proper defendant in future litigation — questions that require corporate discovery to answer.
Damages and Case Value in Roundup Litigation
The value of a Roundup case depends on a constellation of factors — the severity of the diagnosis, the strength of the exposure evidence, the plaintiff’s age and economic profile, the venue, and whether the case is in the MDL settlement program or on an individual litigation track. The range is wide: from compromise settlements in the tens of thousands for weaker-exposure cases to individual jury verdicts exceeding tens of millions for strong-exposure plaintiffs with compelling damages narratives. Some verdicts have included significant punitive damages awards, though several were later reduced on post-trial motions or appeal.
Economic damages in a glyphosate NHL case include:
Past and future medical treatment — chemotherapy, radiation, stem-cell transplant, immunotherapy, ongoing monitoring, and management of treatment side effects. A single stem-cell transplant can cost hundreds of thousands of dollars. CAR-T therapy can cost more. Even with insurance, the out-of-pocket cost of cancer treatment — co-pays, deductibles, uncovered services, travel to treatment centers — is devastating for most families.
Lost wages and diminished earning capacity — the time away from work during treatment, the reduced capacity after treatment, and for patients who cannot return to their prior occupation, the permanent loss of earning power. A farmer who can no longer farm, a landscaper who can no longer do physical labor, a worker in their prime earning years whose career trajectory is permanently altered — these are quantifiable economic losses that a forensic economist projects across the plaintiff’s expected worklife.
Future medical monitoring — even patients in remission require ongoing surveillance: regular CT scans, blood work, and oncology visits. That cost continues for life.
Non-economic damages include:
Pain and suffering — the physical pain of the disease and its treatment. Chemotherapy is not just an abstract medical process — it is nausea, exhaustion, mouth sores, nerve pain, hair loss, and the psychological weight of knowing your body is being poisoned to save your life.
Emotional distress — the fear of relapse, the anxiety of every follow-up scan, the depression that accompanies a cancer diagnosis, the strain on marriages and families.
Loss of quality of life — the activities the plaintiff can no longer do, the energy they no longer have, the future they had planned that now looks different.
Punitive damages have been awarded in glyphosate verdicts where juries found that the manufacturer acted with malice or reckless disregard for human safety — particularly where internal documents suggested the company knew of cancer risk and worked to discredit or suppress the evidence. The Ruveon restructuring may complicate the punitive-damages picture if it is perceived as a liability-shielding maneuver, because a jury that sees a company restructuring its assets while facing thousands of cancer claims may view that as evidence of consciousness of wrongdoing.
Wrongful death and survival actions apply where the plaintiff has died. Each state’s law governs who may bring the claim, what damages are recoverable, and how the recovery is distributed. Wrongful-death deadlines are often shorter than personal-injury deadlines — another reason families should not wait.
We handle these cases on contingency. You pay nothing unless we win. The fee is 33.33% if the case settles before trial and 40% if it goes to trial. That structure means we carry the risk — and it means our interests are aligned with yours. You can read more about how contingency fees work on our personal injury practice page.
The Defendant’s Playbook — and How We Counter It
Bayer and Monsanto have built a sophisticated defense apparatus over years of Roundup litigation. Here are the plays they run — and the counters we bring.
Play 1: “The EPA says glyphosate is safe.”
The defense leads with the EPA’s classification of glyphosate as “not likely to be carcinogenic.” They argue that the federal regulator reviewed the science and found no cancer link, so the lawsuit is an end-run around the regulatory process.
The counter: the EPA is not the only authority on cancer. IARC — the world’s leading cancer research agency — reached a different conclusion. The EPA’s position has been criticized for relying heavily on industry-submitted studies. And the EPA’s registration decision is not a finding that a product is safe in all contexts — it is a regulatory approval based on specific risk-benefit calculations. A manufacturer’s duty to warn is not satisfied by pointing at a regulator that used different standards and reached a different conclusion from the world’s cancer authority.
Play 2: “NHL is common and has many causes — you cannot prove glyphosate caused yours.”
The defense argues that NHL is a common cancer with no single identifiable cause in most cases. They point to genetics, viral infections, other chemical exposures, and immune disorders as alternative explanations. They argue that the plaintiff cannot prove that glyphosate — rather than something else — caused this particular cancer.
The counter: causation in toxic tort cases is built on the weight of the evidence, not a single definitive test. The plaintiff’s oncologist and toxicologist work together to build a specific-causation opinion based on: the plaintiff’s documented exposure history, the dose-response relationship in the epidemiological literature, the absence of other identified risk factors, the timing of exposure relative to diagnosis, and the consistency of the injury with the type of cancer the literature associates with glyphosate. We do not have to prove glyphosate was the only cause — we have to prove it was a substantial contributing cause.
Play 3: “The statute of limitations has expired.”
The defense argues that the plaintiff waited too long to file — that the deadline ran from the date of diagnosis, the date of exposure, or some other triggering event, and that the filing window has closed.
The counter: the discovery rule. In most states, the statute of limitations for a toxic tort claim does not start running on the date of exposure — it starts when the plaintiff discovered, or by reasonable diligence should have discovered, the connection between the injury and the exposure. For a farmworker diagnosed with NHL in 2015 who did not learn about the IARC classification or the potential Roundup-NHL link until reading about it in 2019, the clock may have started in 2019 — not 2015. The discovery rule is jurisdiction-specific, and some states impose an outer statute-of-repose deadline that can cut off a claim even before discovery. This is a question that must be evaluated case by case, state by state. You can learn more about how we handle these cases on our toxic tort claims page.
Play 4: “The restructuring means you sued the wrong entity.”
The defense may argue that the plaintiff named the wrong corporate entity — that Bayer is not the proper defendant, or that Ruveon is now the relevant entity, or that the liability sits in a legacy Monsanto entity that no longer has assets.
The counter: we do not accept corporate restructuring as a shield. We investigate the entity structure, demand the transfer agreements, and plead successor-liability and fraudulent-transfer theories where the facts support them. The company that made and sold Roundup, and the company that acquired that liability, are both within reach. The name on the door does not change the obligation.
Play 5: The quick settlement offer.
In some cases, the defense may extend a settlement offer early — sometimes before the plaintiff has fully evaluated the case, sometimes before the full extent of the damages is known. The offer may look substantial but may be a fraction of what the case is worth once the lifetime medical costs, lost earning capacity, and non-economic damages are fully calculated.
The counter: we evaluate every settlement offer against a full damages model built by a life-care planner and a forensic economist. The first offer is almost always a fraction of the case’s true value. We do not recommend accepting a settlement until we know what the case is actually worth — and that requires building the full picture.
Statute of Limitations: The Clock That Kills Cases Silently
This is the section that matters most to someone reading this page at 2 a.m., wondering if it is too late to call.
The statute of limitations for a Roundup cancer claim is set by your state’s law — and because Roundup cases have been filed across the country, the controlling deadline depends on where you were exposed, where you live, and where your case would be filed. There is no single national deadline.
What we can tell you is how the clock works in most states:
The discovery rule. In most jurisdictions, the statute of limitations for a toxic tort claim does not begin running on the date you were exposed to glyphosate — it begins when you discovered, or through reasonable diligence should have discovered, that your injury (NHL) was connected to your exposure (Roundup use). For many plaintiffs, that discovery came when the IARC classification was published in 2015, when the first Roundup lawsuits were filed and reported in the media, or when they saw a television advertisement connecting Roundup to NHL. The exact trigger is jurisdiction-specific and fact-specific.
The personal-injury deadline. Most states have a personal-injury statute of limitations ranging from one to six years — with two and three years being the most common. Some states have longer deadlines for actions involving latent disease or toxic exposure. The clock starts under the discovery rule, not the exposure date.
The wrongful-death deadline. If your loved one has passed away from NHL, the wrongful-death statute of limitations is typically shorter than the personal-injury deadline — often one to three years from the date of death. This deadline is frequently more rigid, with less room for discovery-rule arguments. If your family member died and had a history of Roundup use, do not wait to call. The wrongful-death clock may be running right now.
The statute of repose. Some states impose an outer deadline — a statute of repose — that can bar a claim even if the discovery rule has not yet started the limitations clock. A repose statute sets an absolute time limit from the date of exposure (or the date the product was sold) after which no claim can be brought, regardless of when the injury was discovered. Not all states have repose statutes for product liability, and the ones that do vary in their length and scope. This is a critical question that must be answered for your specific state.
The Supreme Court factor. The pending decision in Monsanto v. Durnell could reshape the legal landscape for Roundup claims. If you are considering a claim, filing before the decision is issued may place you in a stronger procedural posture than filing after — because a decision that restricts state-law claims could affect cases filed after the ruling differently than those already in the system.
The honest summary: the deadline in your state is real, it is running, and it may be shorter than you think. The only way to know for certain is to have a lawyer evaluate your specific situation — your state, your exposure history, your diagnosis date, and when you first learned of the potential Roundup-NHL connection. That evaluation is free. Call us at 1-888-ATTY-911.
How a Roundup Case Is Built — the Proof Story
Here is how a glyphosate case is actually assembled, from the first call to resolution:
Week one: the intake and exposure history. When you call, we take a detailed exposure history. When did you first use Roundup? How often? What concentration? What equipment — a hand sprayer, a backpack sprayer, a tractor-mounted rig? Did you mix the concentrate yourself? Did you wear gloves, a mask, protective clothing? Where did you use it — farm fields, residential property, commercial job sites? How many years did you use it? We document every detail, because the exposure reconstruction is the foundation of the causation opinion.
The medical records. We pull your complete medical file — the pathology report from your biopsy, your treatment records, your oncologist’s notes, your imaging, your blood work. The pathology report identifies the specific NHL subtype, which matters because the scientific literature on glyphosate and NHL is subtype-specific in some studies. The treatment records establish the medical costs and the human toll.
The expert team. A qualified oncologist reviews your medical records and provides a specific-causation opinion — that your NHL is consistent with glyphosate exposure based on the literature, your exposure history, and the absence of other identified risk factors. A toxicologist reviews the exposure history and provides a dose-reconstruction opinion — that your cumulative exposure was sufficient to plausibly contribute to the development of NHL. A life-care planner projects your future medical needs and costs. A forensic economist calculates your lost earning capacity and reduces all future costs to present value.
The corporate discovery. In the MDL, a massive cache of Monsanto internal documents has already been produced — internal communications about glyphosate research, IARC response strategy, regulatory lobbying, and marketing decisions. These documents are available to plaintiffs in the coordinated proceedings. For cases on the individual track, we demand the same documents through discovery. The Ruveon restructuring adds a new layer: we demand the restructuring documents — the entity-formation filings, the asset-transfer agreements, and the internal communications about the purpose and timing of the reorganization.
The depositions. Corporate witnesses — Monsanto scientists, regulatory affairs personnel, marketing executives, and now potentially Ruveon’s management — are deposed under oath about what the company knew about glyphosate’s cancer risk, when it knew it, and what it did (or did not) do to warn users. The internal documents guide the questions. The answers, given under oath, become the testimony that a jury hears.
The mediation or the trial. Many Roundup cases resolve through the MDL settlement program or through individual mediation. For strong-exposure plaintiffs with compelling damages narratives, the individual trial track may yield higher value — because a jury that hears the full story of years of exposure, a devastating cancer diagnosis, and a company that restructured its business while facing thousands of claims may return a verdict that far exceeds any settlement offer. The decision of whether to settle or try a case is yours — we give you our honest evaluation, and you decide.
Your First Steps — What to Do Now
If you used Roundup and were diagnosed with non-Hodgkin lymphoma, here is what you should do — and what you should not do:
Do:
Call a lawyer. The consultation is free, and the statute of limitations in your state is running. The single most important step is finding out whether you still have time to file. Call 1-888-ATTY-911.
Gather your medical records — especially the pathology report from your biopsy, which identifies your specific NHL subtype. If you do not have it, your oncologist’s office can provide it.
Write down your exposure history while it is fresh in your memory. Every detail matters: what brands you used, how often, for how many years, what equipment, whether you mixed concentrate, whether you wore protective gear. Do this now — not in six months, when the details have faded.
Photograph any remaining product containers you have. The label is evidence.
Talk to co-workers or family members who can confirm your Roundup use. Their recollections are witness statements.
Do not:
Do not sign anything from Bayer, Monsanto, Ruveon, or any claims administrator without having a lawyer review it. A release signed today may extinguish rights you do not even know you have.
Do not give a recorded statement to any insurance representative or claims adjuster. Their questions are designed to limit liability, not to help you.
Do not post about your case on social media. Everything you post can be discovered and used by the defense.
Do not wait. The evidence in your case — your memory, your witnesses’ memories, your product containers, your medical timeline — is not getting stronger. And the deadline in your state is not getting longer.
Frequently Asked Questions
Does the Bayer-Ruveon restructuring mean I can no longer sue Bayer for my Roundup cancer?
No. Corporate restructuring does not eliminate your legal rights. Bayer remains the parent entity and the successor to Monsanto’s liabilities. A new subsidiary does not shield the parent from claims based on conduct that occurred before the restructuring. What the restructuring does is add a layer of corporate complexity that requires investigation — and your lawyer needs to understand the new structure to name the right entities and pursue the right theories. The obligation to the people who were injured does not change because the org chart did.
I used Roundup years ago and just now learned it might be linked to my non-Hodgkin lymphoma. Is it too late to file?
It may not be. In most states, the statute of limitations for a toxic tort claim starts when you discovered — or should have discovered through reasonable diligence — the connection between your injury and the exposure. If you only recently learned about the potential Roundup-NHL link, the clock in your state may have started recently, not on the date you were diagnosed. However, every state is different, and some states have statutes of repose that impose an absolute outer deadline. The only way to know for certain is to call us for a free evaluation of your specific situation.
Can I still file a claim if my loved one died from non-Hodgkin lymphoma?
Yes, but the deadline may be shorter. Wrongful-death statutes typically have their own limitations periods — often one to three years from the date of death — and these deadlines are sometimes more rigid than personal-injury deadlines. If your family member used Roundup and died from NHL, do not wait. The wrongful-death clock may be running right now. We can evaluate the deadline for your state and tell you honestly whether there is still time.
What is the Monsanto v. Durnell Supreme Court case, and does it affect my claim?
Monsanto v. Durnell is a pending Supreme Court case (No. 24-1068) that asks whether FIFRA — the federal pesticide-labeling law — expressly preempts state-law failure-to-warn claims against Roundup manufacturers. The Supreme Court heard oral argument in April 2026 and a decision is expected by the end of the term. If the Court rules for Monsanto, state-law failure-to-warn claims could be restricted. If the Court rules for the plaintiffs, the existing litigation pathway continues. Because the case is undecided, we do not state an outcome — but if you are considering a claim, filing before the decision may place you in a stronger position than filing after.
Do I have to be a farmer or professional applicator to have a Roundup claim?
No. While agricultural workers and professional landscapers typically have the strongest exposure profiles because of the volume and duration of their use, homeowners and gardeners who used Roundup regularly over many years may also have viable claims. The key question is whether your exposure was sufficient and sustained enough to plausibly contribute to the development of your NHL. That is a case-specific evaluation that depends on your usage history, your diagnosis, and the scientific literature.
How much is a Roundup cancer case worth?
The value depends on the severity of the diagnosis, the strength of the exposure evidence, the plaintiff’s age and economic profile, the venue, and whether the case is in the settlement program or on the individual litigation track. Cases have ranged from compromise settlements in the tens of thousands to individual jury verdicts exceeding tens of millions — with some verdicts including significant punitive damages, though several were later reduced on appeal. We evaluate each case individually, building a full damages model with a life-care planner and a forensic economist. Past results depend on the facts of each case and do not guarantee future outcomes.
What if I do not have receipts proving I bought Roundup?
Receipts are helpful but not essential. Exposure can be established through witness testimony — co-workers, family members, and neighbors who can describe your Roundup use. Employment records may document your duties if you used Roundup as part of your job. Credit card statements may show purchases from hardware stores or agricultural supply companies. The key is to document what you can remember and what others can confirm. We help you build the exposure picture from whatever sources are available.
Will I have to go to trial?
Most Roundup cases resolve through settlement — either through the MDL settlement program or through individual negotiation. But some cases go to trial, particularly strong-exposure cases where the plaintiff’s damages narrative is compelling and the settlement offer does not reflect the full value of the case. The decision of whether to settle or go to trial is always yours. We give you our honest evaluation, build the case to be trial-ready, and let you decide. A case that is prepared for trial from day one is also the case that commands the best settlement offer.
How do I pay for a lawyer?
We work on contingency. The consultation is free. We do not get paid unless we win your case. The fee is 33.33% if the case settles before trial and 40% if it goes to trial. We advance the costs of building the case — the expert fees, the filing fees, the discovery expenses — and those costs are repaid from the recovery. If there is no recovery, you owe us nothing for our time. You can learn more about how contingency fees work by visiting our contact page or calling 1-888-ATTY-911.
Why This Firm
We are Attorney911 — The Manginello Law Firm, PLLC. We are Legal Emergency Lawyers. We have been taking on corporate defendants and insurance companies since 2001.
Ralph Manginello is our managing partner — 27+ years of trial practice, licensed in Texas since 1998, admitted to federal court in the Southern District of Texas. He was a journalist before he was a lawyer, which means he knows how to find the story the documents tell and how to tell it to a jury. He handles toxic tort and product-liability cases with the same intensity he brings to every catastrophic-injury and wrongful-death case on our docket. You can read more about Ralph Manginello here.
Lupe Peña is our associate attorney — a former insurance-defense lawyer who spent years on the other side of the table, inside the rooms where adjusters and their software decided how to deny, delay, and devalue claims. He knows how the defense evaluates a case, how it sets reserves, how it picks its experts, and how it designs its settlement strategy — because he used to do it. Now he uses that knowledge for injured people. Lupe is fluent in Spanish and conducts full consultations in Spanish without an interpreter. You can read more about Lupe Peña here.
We handle these cases on contingency — 33.33% before trial, 40% if we go to trial. You pay nothing unless we win. The consultation is free, and it is confidential. We have live staff answering our phones 24 hours a day, 7 days a week — not an answering service, real people who can take your information and get you to a lawyer. Hablamos Español.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Every case is different, and the outcome of your case depends on the specific facts of your situation, the law of your state, and the decisions made by the courts and the parties involved.
Call Now
If you used Roundup and developed non-Hodgkin lymphoma — or if someone you love did — the time to call is now. Not next month. Not after the Supreme Court rules. Not after you see whether the Ruveon restructuring changes anything. Now.
The evidence in your case has a shelf life. The witnesses’ memories fade. The statute of limitations in your state is running. And the corporate restructuring that Bayer just announced is building new walls between you and the company that profited from the product that may have made you sick. Every day you wait is a day the defense uses to prepare — and a day you lose that you cannot get back.
Call 1-888-ATTY-911. The call is free. The consultation is free. We do not get paid unless we win your case.
We will tell you honestly whether you have a case, what it might be worth, and how long you have to decide. If we are not the right fit for your situation, we will tell you that too — and point you in the right direction. That is what an honest lawyer does.
Attorney911 — The Manginello Law Firm, PLLC. Legal Emergency Lawyers. 1-888-ATTY-911. Hablamos Español.